New hope for tough blood cancers: early trial tests BT02
NCT ID NCT07107204
Summary
This early-stage study aims to test the safety and early effectiveness of an investigational drug called BT02 for adults with blood cancers that have returned or not responded to previous treatments. Participants will receive BT02 through an IV every few weeks for up to two years if they tolerate it well. The main goals are to find a safe dose and see if the treatment helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.